Total Funding
94
78
Total FundingSeries C raised
Growth Score
2 pts
Heat Score
11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
3517
Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.
- Johan H. Faber: CTO & Co-Founder
- Benny Sørensen: Chief Executive OfficerPast Role: Codiak Biosciences, Senior Vice President, Head of Clinical Development and Strategic Projects
About the Company
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening
complications.
